P990056/S046: ELECSYS TOTAL PSA IMMUNOASSAY AND TOTAL PSA CALSET
FDA’s recorded scope: manufacturing and testing improvements to the Elecsys Streptavidin (SA)-coated microparticles
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 4 FDA records to the applicant name Roche Diagnostics Corp.. 4 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Feb 27, 2026 to Apr 29, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LTJ appears in 2 of the 4 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P000027, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 9115 Hague Rd., Indianapolis, IN, 46250. Recorded on P990056/S046, decision dated Apr 29, 2026.
Total, Prostate Specific Antigen (Noncomplexed & Complexed) For Detection Of Prostate Cancer; PROSTATE-SPECIFIC ANTIGEN (PSA) FOR MANAGEMENT OF PROSTATE CANCERS.
FDA’s recorded scope: manufacturing and testing improvements to the Elecsys Streptavidin (SA)-coated microparticles
FDA’s recorded scope: manufacturing and testing improvements to the Elecsys Streptavidin (SA)-coated microparticles
FDA’s recorded scope: To add another location for a process within the same establishment.
FDA’s recorded scope: To add another location for a process within the same establishment.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Roche Diagnostics Corp. | PMA supplement | Apr 29, 2026 | FDA | |
ELECSYS FREE PSA IMMUNOASSAY/CALSET/CALCHECKP000027/S045 | Roche Diagnostics Corp. | PMA supplement | Apr 29, 2026 | FDA |
Elecsys total PSA assayP990056/S045 | Roche Diagnostics Corp. | PMA supplement | Feb 27, 2026 | FDA |
Elecsys free PSA assayP000027/S044 | Roche Diagnostics Corp. | PMA supplement | Feb 27, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 20, 2026.